1 / 66

HYPERTENSIVE DISORDERS OF PREGNANCY

HYPERTENSIVE DISORDERS OF PREGNANCY. A/Prof Sandra Lowe. What’ s old What’ s new What does it mean to your practise?. What’s old?. Incidence of hypertensive disorders. In Australia: Any HT disorder 9.8% Chronic HT 0.6% Preeclampsia 4.2% Eclampsia 0.1% Gestational HT 4.3%

rmoyer
Télécharger la présentation

HYPERTENSIVE DISORDERS OF PREGNANCY

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. HYPERTENSIVE DISORDERS OF PREGNANCY A/Prof Sandra Lowe

  2. What’ s old What’ s new What does it mean to your practise?

  3. What’s old?

  4. Incidence of hypertensive disorders • In Australia: • Any HT disorder 9.8% • Chronic HT 0.6% • Preeclampsia 4.2% • Eclampsia 0.1% • Gestational HT 4.3% • Chronic HT + preeclampsia 0.3% MJA, 2005:182(7):332-335 Am J Obstet Gynecol 2013

  5. Major maternal and neonatal morbidityChronic Chronic PE GH No HT + PE % % % % % APH 0.9 1.4 1.5 0.9 0.8 Severe PPH 0.8 1.0 1.6 0.9 0.7 ARF/ALF/I 0.1 0.4 0.5 0.2 0.1 ICU 0.3 2.2 2.0 0.3 0.1 Major M&M 1.8 4.8 6.4 2.1 1.6 Major neonatal morbidity or mortality 6.1 14.1 9.2 3.1 3.3 Roberts CL, MJA, 2005:182(7):332-335

  6. Maternal mortality • RR for women with preeclampsia/ eclampsia dying in the first 12 months following birth when compared with normotensive women of 5.1 (95% CI, 3.07- 8.60). • All cause maternal deaths within 12 months: 17/97 =18% had experienced preeclampsia. • Deaths within 42 days of birth: 5/30=17% had experienced preeclampsia.

  7. Definition of hypertension in pregnancy • Systolic ≥ 140 mmHg and/or diastolic ≥ 90 mmHg (K5) • Which is more important: systolic or diastolic ? • In the 24 patients being treated immediately before stroke, systolic pressure was 160 mm Hg or greater in 23 (95.8%) and more than 155 mm Hg in 100%. In contrast, only 3 of 24 patients (12.5%) exhibited prestroke diastolic pressures of 110 mm Hg or greater, only 5 of 28 reached 105 mm Hg, and only 6 (25%) exceeded a mean arterial pressure of 130 mm Hg before stroke. O & G 2005,105(2):246-54 • Renal function in women with severe preeclampsia was significantly impaired and highly correlated with systolic or diastolic blood pressure. Hypertension in Pregnancy. 24(3):247-57, 2005.

  8. Does a rise of 30/15mmHg predict preeclampsia? AM J OG 1989,160(2):419-23. • Does warrant closer observation

  9. Severe hypertension requiring urgent treatment • ≥170 or /110 mmHg • level of blood pressure above which cerebral autoregulation is overcome in normotensive individuals. • associated with a risk of cerebral haemorrhage and hypertensive encephalopathy HT. 2007 Jul;50(1):14-24.

  10. Serial brain MRI of a patient with eclampsia 1 2 3 1 and 2 Increasing cerebral oedema posterior cerebral cortex 3 After IV gadolinium contrast demonstrating disruption of the blood-brain barrier.

  11. Classification Preeclampsia Gestational Hypertension Chronic Hypertension Chronic Hypertension with superimposed preeclampsia

  12. Classification • Preeclampsia • HT after 20 weeks gestation plus involvement of one or more of the following systems • Renal-proteinuria, raised creatinine, oliguria • Haematological- thrombcytopenia, hemolysis, DIC • Liver: raised AST,ALT, upper abdominal pain • Neurological: eclampsia, hypereflexia with clonus, severe headache, visua; disturbance, stroke • Pulmonary edema • Fetal growth restriction • Placental abruption

  13. Dipstick proteinuria needs to be confirmed by spot urine  30mg/mmol or 24 hr urine 300mg/day Hyperuricemia is not diagnostic

  14. Pathophysiology • Phase 1: • failure of trophoblast invasion into spiral arteries prior to 20 weeks • hypoxic & dysfunctional placenta • Phase 2: • Placenta releases factor(s) into maternal circulation endothelial inflammatory response with endothelial dysfunction, increased oxidative stress • Phenotype: • Mixture of maternal and fetal syndrome

  15. Whats new?

  16. Search for the preeclampsia circulating factor Current putative factors: Imbalance between angiogenic growth factors VEGF and PlGF and soluble placental derived anti-angiogenic factors such as sFlt-1 and endoglin VEGF vascular endothelial growth factor PlGF placental growth factor sFlt-1 soluble fms-like tyrosine kinase 1: VEGF and PlGF receptor Endoglin: TGF (transforming growth factor) b1 and b3 co-receptor

  17. In women with preeclampsia, excess sFlt 1 binds VEGF and PlGF : • Antiangiogenic • Blocks VEGF-mediated vasodilation • The antagonism of both PlGF and VEGF is necessary to create the maternal syndrome of preeclampsia Excess SFlt1 explains hypertension and proteinuria in preeclampsia

  18. Mean Concentrations of Soluble fms-like Tyrosine Kinase 1 (sFlt-1) and Placental Growth Factor (PlGF) According to Preeclampsia Status and Severity Levine, R. et al. N Engl J Med 2004;350:672-683

  19. Fetal growth restriction and angiogenic factors Early onset <34 weeks Am J OG 2006; 195,1 Crispi et al Late onset >34 weeks Am J OG 2006; 195,1 Crispi et al

  20. “isolated IUGR with no maternal disease is also associated with changes in placental angiogenic factors and subclinical endothelial dysfunction. “ • Stresses the importance of maternal predisposition for manifestation of maternal syndrome

  21. Management of hypertensive disorders of pregnancy THE MANAGEMENT OF HYPERTENSIVE DISORDERS OF PREGNANCY 2014 • Prev version : ANZJOG 2009; 49: 242–246

  22. Investigation of new onset HT • Assess clinically • Admit: • Preeclampsia • Severe HT or other symptoms • Concerns re fetal well-being • Investigations: • Spot urine PCR • Full blood count • Creatinine, electrolytes, urate • Liver function tests • Ultrasound assessment of fetal growth, amniotic fluid volume and umbilical artery Doppler assessment.

  23. Further assessment depending on diagnosis • Normal: reassess 3-7 days

  24. Clinical role of measuring angiogenic factors • Potential role: • Prediction-T1 • Diagnosis: • Differentiating CKD, CHT, other conditions • Management: • Predicting the need for delivery

  25. Prediction of preeclampsia • Best for early onset disease, but this only comprises 10% of hypertensive disorders of pregnancy • Must be relevant for the full spectrum of women with preeclampsia, including not only those presenting with hypertension and proteinuria but the 26% manifesting primarily as hypertension with another multisystem complication • Local normal ranges for parameters such as PlGF

  26. Diagnosis of HDP • Analogous to troponin for MI • Indicator of adverse outcome • Early data suggests outperforms current indicators eg BP, proteinuria, plat count etc ; esp in early onset disease Circulation.2012; 125: 911-919 • May be useful to discriminate CKD, thrombocytopenia, ??SLE from superimposed preeclampsia

  27. Management of women who present with suspected pre-eclampsia • PELICAN: • Prospective multicenter study of plasma PlGF in women presenting with suspected preeclampsia between 20 and 35 weeks' gestation (and up to 41 weeks' gestation as a secondary analysis). • Outcome was predicting delivery for confirmed preeclampsia within 14 days • N=625 • 55% developed confirmed preeclampsia • In 287 women, PlGF <5th centile had high sensitivity (0.96; 95% confidence interval, 0.89-0.99) and negative predictive value (0.98; 0.93-0.995) • specificity was lower (0.55; 0.48-0.61). • Better for predicting preeclampsia than all other commonly used tests, singly or in combination Circulation, 2013: 18(19):2121-31

  28. Prognostic performance

  29. Other studies • Rana et al: • N= 616 women • sFlt1 and PLGF, sFlt1/PlGF ratio • sFlt1/PlGF ratio at presentation was elevated in participants who experienced any adverse outcome compared with those who did not (47.0 [25th–75th percentile, 15.5–112.2] versus 10.8 [4.1–28.6]; P<0.0001. • <34 weeks (n=167) • any adverse outcome 226.6 [50.4–547.3] versus 4.5 [2.0–13.5]; P<0.0001 • addition of sFlt1/PlGF ratio to hypertension and proteinuria significantly improved the prediction for subsequent adverse outcomes (area under the curve, 0.93 for hypertension, proteinuria, and sFlt1/PlGF versus 0.84 for hypertension and proteinuria alone; P=0.001). • Delivery occurred within 2 weeks of presentation in 86.0% of women with an sFlt1/PlGF ratio ≥85 compared with 15.8% of women with an sFlt1/PlGF ratio <85 (HR, 15.2; [8.0–28.7]) Circulation , 2012: 125(7): 911-919.

  30. Subgroup analysis for diagnosis of PE or superimposed PE • Area under ROC for low PLGF • CHT alone or CKD±CHT: 0.89 SE(0.07) • Serum creat didn’t affect PLGF • PPV : 88% • NPV: 91% • Sens 47% Bramham et al, Abstract

  31. Management of preeclampsia and gestational hypertension • Before 34 weeks: • Delivery is the definitive management • Prolongation of pregnancy is desirable at least to administer corticosteroids for fetal lung maturation • Continuation of pregnancy carries risks • Management should be in a Unit with appropriate expertise

  32. Preeclampsia before 34 weeks Churchill D: Cochrane Database of Systematic Reviews. 7:CD003106, 2013

  33. Management between 34 and 36+6 weeks • Uncertain • Hypitat II: • Severe GH, mild PE, deteriorating CH Awaiting: PHOENIX : Similar UK trial early stages of recruitment

  34. Management between 36-41 weeks • HYPITAT I: • Multi-centred randomised trial • Singleton pregnancy, PIH or mild preeclampsia between 360 and 410 weeks • IOL or expectant monitoring until onset of labour • n=756 • Netherlands The Lancet, 2009, 374 [9694]: 979 – 988.

  35. No maternal deaths or eclampsia Most of benefit was reduced incidence of severe HT No significant difference in neonatal outcomes

  36. Impact of Hypitat • Induction of labour increased from 58.3 to 67.1% (P < 0.001) • Prevalence of eclampsia decreased from 0.85 to 0.19% (P < 0.001) • Risk of caesarean delivery after labour induction between women with favourable and unfavourable cervices was equal in IOL group • Women with an unfavourable cervix benefited more from labour induction than other women. • Women who were managed expectantly, the longer the cervix the higher the rate of LSCS and the greater the risk of developing maternal high-risk situations

  37. Timing of delivery and gestation of presentation of preeclampsia

  38. Management principles • Team approach to management • Determine clear “endpoints” for delivery for each patient • Control HT and other maternal derangements before delivery

  39. Treatment of hypertension • What blood pressure target do you aim for ? • Recommend treatment for all women ≥160 systolic or 100 diastolic • Treat BP ≥170mm Hg systolic or 110mmHg diastolic urgently • Consider treatment 140-159 or /90-99 mm Hg

  40. Antihypertensive treatment Severe HT: treat urgently

  41. Give long acting agents concurrently All Units should have protocols for management of severe hypertension

  42. Controversy regarding treatment of mild-moderate hypertension • In favour: • blood pressure may be extremely labile in preeclampsia and treatment at lower blood pressure levels will prevent or attenuate acute and severe rises in blood pressure • in addition, it is possible that pharmacologic arteriolar vasodilation may help improve organ perfusion • Against: • little risk to the mother in having relatively mild hypertension for a short time • fetal perfusion is dependent upon adequate maternal blood pressure • lowering blood pressure suppresses an important sign of the severity or progression of preeclampsia.

  43. CHIPS • Randomised trial of less tight v tight control of BP • GA at randomisation: 4-33 weeks • Chronic or gestational HT • N=987 • Target diastolic 100 v 85 mmHg • Actual BP achieved- • 138.8 v 133 systolic • 89.9 v 85.3 diastolic • Results: • No difference in pregnancy loss, serious maternal complications, BW or SGA, admission to Neonatal nursery >48 hrs • Incidence of severe HT >160/110mHg : • Tight control 27.5% v less-tight 40.6%**

  44. Ongoing treatment for hypertension

  45. Other aspects of management • Thromboprophylaxis • Intravenous fluids • Cautious, carefully monitored • Women with severe preeclampsia immediately prior to parenteral hydalazine, regional anaesthesia or immediate delivery • Initial management in women with oliguria where there is a suspected or confirmed deficit in intravascular volume • Crystalloid or colloid

  46. Haematologic and hepatic manifestations • Platelet transfusion for severe thrombocytopenia at the time of Caesarean delivery, PPH, wound or vulval hematoma or other bleeding • FFP &/or cryoprecipitate for management of coagulopathy indicated by active bleeding and a prolonged APTT and INR • Steroid therapy is not indicated for management of thrombocytopenia or hepatic involvement  

  47. Eclampsia • Eclampsia 4.2% of preeclamptics • Antenatally 25.1% • During labor 44.1% • Postnatally 26.3% • Not specified 4.5% • . • Comprehensive protocols required in each Unit • Resuscitation • Prevention with Mg Sulfate • Control HT • Plan delivery • Prevention: local policy re Mg sulphate • In Aust and NZ: low morbidity from eclampsia • High NNT

  48. Fetal Surveillance

More Related